设为首页  |  加入收藏
 
  首 页
 学科带头人 
 学科骨干 
 
  当前位置:内容页面  
张英起
2010-07-15 15:35   发布范围:公开

张英起,男,博士,现为第四军医大学药学系生物制药学教研室主任,教授,博士研究生导师。1983年毕业于第四军医大学医疗系,1986年和1991年分别获得第四军医大学生物化学与分子生物学专业硕士和博士学位。现任国家肿瘤生物学国家重点实验室(第四军医大学)肿瘤靶向单元PI;第四军医大学分子医学中心生物工程药物研究室主任;任中国生物化学与分子生物学学会工业分会常务理事,分子生物学与基因工程专业委员会主任委员;全军生物技术专业委员会副主任委员;全军微生物与生化药学专业委员会副主任委员;陕西省生物化学与分子生物学学会常务理事兼秘书长。

研究方向 抗肿瘤治疗的基础研究及基因工程药物的开发研究

承担国家课题

1、重组人干扰素a2a与肿瘤新生血管结合多肽NGR融合蛋白的临床前研究  

重大新药创制”科技重大专项(No. 2009ZX09102-225  负责人

2、保密课题  重大新药创制”科技重大专项—军队特需药品保密专项课题(课题编号:2008ZXJ09004-025  负责人

3、Foxp3通过UXT负向调控NF-κB的转录活性及其复合物在调节性T细胞中的生物学意义    国家自然科学基金(No.30972672  负责人

代表性论著

1. Li M, Qin X, Xue X, Zhang C, Yan Z, Han W, Komarck C, Wang TD, Zhang Y. Safety evaluation and pharmacokinetics of a novel human tumor necrosis factor-alpha exhibited a higher antitumor activity and a lower systemic toxicity. Anticancer Drugs. 2010 Mar;21(3):243-51.

2. Zhang XY, Wang S, Yan Z, Zhang YQ, Wan Y, Zhang B, Wang LF, Chai YB, Wei JG. Promoter cloning and characterization of the rabbit BK channel beta1 subunit gene. Gene. 2009 Jun 1;438(1-2):33-9.

3.Liu N, Wang L, Li X, Yang Q, Liu X, Zhang J, Zhang J, Wu Y, Ji S, Zhang Y, Yang A, Han H, Yao L.N-Myc downstream-regulated gene 2 is involved in p53-mediated apoptosis.Nucleic Acids Res. 2008 Sep;36(16):5335-49.

4.Xue X, Feng G, Li M, Qin X, Wu S, Zhang C, You Y, Wang W, Jiang C, Liu Y, Zhu W, Ran Y, Zhang Z, Yan Z, Han W, Zhang Y. Amelioration of experimental autoimmune encephalomyelitis by BLyS autovaccine.Vaccine. Vaccine. 2008 Jun 2;26(23):2873-81.

5.Wang L, Liu N, Yao L, Li F, Zhang J, Deng Y, Liu J, Ji S, Yang A, Han H, Zhang Y, Zhang J, Han W, Liu X. NDRG2 is a new HIF-1 target gene necessary for hypoxia-induced apoptosis in A549 cells. Cell Physiol Biochem. 2008;21(1-3):239-50.

6.Wang T, Zhao J, Ren JL, Zhang L, Wen WH, Zhang R, Qin WW, Jia LT, Yao LB, Zhang YQ, Chen SY, Yang AG. Recombinant immunoproapoptotic proteins with furin site can translocate and kill HER2-positive cancer cells. Cancer Res. 2007;67(24):11830-9.

7.Liu N, Wang L, Liu X, Yang Q, Zhang J, Zhang W, Wu Y, Shen L, Zhang Y, Yang A, Han H, Zhang J, Yao L.Promoter methylation, mutation, and genomic deletion are involved in the decreased NDRG2 expression levels in several cancer cell lines. Biochem Biophys Res Commun. 2007;358(1):164-9

8.Huo Y, Li B, Zhang Y, Wang S, Bao M, Gao X, Li D, Wang L, Yu Y, Wang J. Pre-clinical safety evaluation of heat shock protein 65-MUC1 peptide fusion protein. Regul Toxicol Pharmacol. 2007 ;49(1):63-74.

9.Qin X, Li M, Xue X, Yan Z, Han W and Zhang Y. Identification of a novel peptideligand of human vascular endothelia growth factor receptor 3 for targeted tumor diagnosis and therapy. FEBS Journal. 2007, 274(Sup 1): 281p

10.Li M, Han W, Zhang Q, Xue X, Wang Z, Zhang Y. Development of a mimotope-based vaccine against CD20 antigen. Protein Pept Lett. 2007;14(6):610-4.

11.Wan Y, Xue X, Li M, Zhang X, Qin X, Zhang C, You Y, Wang W, Jiang C, Wu S, Liu Y, Zhu W, Ran Y, Zhang Z, Han W, Zhang Y. Prepared and screened a modified TNF-alpha molecule as TNF-alpha autovaccine to treat LPS induced endotoxic shock and TNF-alpha induced cachexia in mouse. Cell Immunol. 2007 ;246(2):55-64.)

12.Tang L, Yan Z, Wan Y, Han W, Zhang Y. Myostatin DNA vaccine increases skeletal muscle mass and endurance in mice. Muscle Nerve. 2007;36(3):342-8.

13.Qin X, Wan Y, Li M, Xue X, Wu S, Zhang C, You Y, Wang W, Jiang C, Liu Y, Zhu W, Ran Y, Zhang Z, Han W, Zhang Y. Identification of a novel peptide ligand of human vascular endothelia growth factor receptor 3 for targeted tumour diagnosis and therapy. JBiochem . 2007 ;142(1):79-85.

14.J Meng, Z Yan, J Wu, L Li, X Xue, M Li, W Li, Q Hao, Y Wan, X Qin, W Han, Y Zhang. High-yield expression, purification and characterization of tumor-targeted IFN-α2a. Cytotherapy. 2007;9(1):60-68.

15.Yan Z, Zhao N, Wang Z, Li B, Bao C, Shi J, Han W, Zhang Y. A mutated human tumor necrosis factor-alpha improves the therapeutic index in vitro and in vivo. Cytotherapy. 2006;8(4):415-23.

16.Meng J, Ma N, Yan Z, Han W, Zhang Y. NGR enhanced the anti-angiogenic activity of tum-5. J Biochem. 2006;140(2):299-304.

17.Li M, Yan Z, Han W, Zhang Y. Mimotope vaccination for epitope-specific induction of anti-CD20 antibodies. Cell Immunol. 2006;239(2):136-43

18.Yan Z, Lu L, Shi J, Bao C, Han W, Wu Y, Zhang Y. Expression, refolding, and characterization of GFE peptide-fused human interferon-alpha2a in Escherichia coli. Appl Biochem Biotechnol. 2006 ;133(2):149-62.

19.Wu K, Xue X, Wang Z, Yan Z, Shi J, Han W, Zhang Y. Construction, purification, and immunogenicity of recombinant cystein-cystein type chemokine receptor 5 vaccine. Protein Expr Purif. 2006 ;49(1):108-13.

20.Wang H, Yan Z, Shi J, Han W, Zhang Y. Expression, purification, and characterizationof a neovasculature targeted rmhTNF-alpha in Escherichia coli. Protein Expr Purif. 2006;45(1):60-5.

21.Hou D, Yan Z, Shi J, Han W, Zhang Y. Expression and one-step ion-exchange purification of (AAR)IL-8 (human IL-8 receptor antagonist). Protein Expr Purif. 2005;44(2):104-9.21.

22.Xue X, Wang Z, Yan Z, Shi J, Han W, Zhang Y. Production and purification of recombinant human BLyS mutant from inclusion bodies.Protein Expr Purif. 2005;42(1):194-9.

授权发明专利

1.肿瘤血管导向肽与人干扰素α-2b的融合蛋白的制备方法ZL200510043192.5

2.肿瘤新生血管特异性结合多肽与人α干扰素融合蛋白及制备  ZL02139537.3

3.肿瘤新生血管特异性结合多肽CRGDC与新型重组人肿瘤坏死因子nrhTNF融合蛋白及制备方法 ZL200510096374

4.肿瘤新生血管特异性结合多肽与重组人Tum-5融合蛋白及其制备方法ZL200510096389.

5.人B细胞特异性膜分子CD20的12氨基酸模拟表位及其用该模拟表位构建的多肽表位疫苗  ZL200510096370.0

6.人白细胞介素8拮抗蛋白及其制备方法  ZL200510096373.4

7.破伤风毒素T细胞表位多肽与人B淋巴细胞刺激因子融合蛋白及其制备ZL200510096372.X

8.重组人His-TT-B7-H1IgV肿瘤疫苗及其制备方法 ZL200610105039.5

9.一种Myostatin特异性抗体的治疗性疫苗及其制备方法 ZL200610104728.4

科研成果

1、注射用重组改构人肿瘤坏死因子  2003年获国家I类新药证书(国药准字S20030019)

2、重组改构人肿瘤坏死因子        2004年获陕西省科技进步一等奖

出版专著

1、黄晓峰,张远强,张英起 主编  《荧光探针技术 》人民军医出版社 北京 2004.5

2、颜真,张英起,薛晓畅主编  蛋白质研究技术 第四军医大学出版社 西安 2007.1

研究生培养

培养硕士研究生23名,博士研究生16名

关闭窗口
   
 
 联系我们 | 网站地图 | 返回首页 

版权所有:第四军医大学 学校地址:西安市长乐西路17号
电子邮箱:webmaster@fmmu.edu.cn 陕ICP备05006911号